Assenagon Asset Management’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.3K | Sell |
36,801
-17,625
| -32% | -$7.82K | ﹤0.01% | 1124 |
|
|
2025
Q1 | $30.8K | Sell |
54,426
-15,373
| -22% | -$8.7K | ﹤0.01% | 1123 |
|
|
2024
Q4 | $147K | Sell |
69,799
-132,516
| -65% | -$280K | ﹤0.01% | 1264 |
|
|
2024
Q3 | $544K | Sell |
202,315
-25,386
| -11% | -$68.3K | ﹤0.01% | 1197 |
|
|
2024
Q2 | $649K | Buy |
227,701
+150,218
| +194% | +$428K | ﹤0.01% | 1167 |
|
|
2024
Q1 | $329K | Hold |
77,483
| – | – | ﹤0.01% | 1237 |
|
|
2023
Q4 | $415K | Sell |
77,483
-21,271
| -22% | -$114K | ﹤0.01% | 1229 |
|
|
2023
Q3 | $425K | Sell |
98,754
-35,896
| -27% | -$154K | ﹤0.01% | 1185 |
|
|
2023
Q2 | $739K | Buy |
134,650
+72,499
| +117% | +$398K | ﹤0.01% | 1005 |
|
|
2023
Q1 | $261K | Buy |
+62,151
| New | +$261K | ﹤0.01% | 1286 |
|
|
2022
Q4 | – | Sell |
-22,377
| Closed | -$57K | – | 1345 |
|
|
2022
Q3 | $57K | Sell |
22,377
-22,205
| -50% | -$56.6K | ﹤0.01% | 1258 |
|
|
2022
Q2 | $160K | Buy |
44,582
+13,929
| +45% | +$50K | ﹤0.01% | 1348 |
|
|
2022
Q1 | $190K | Sell |
30,653
-94,987
| -76% | -$589K | ﹤0.01% | 1313 |
|
|
2021
Q4 | $886K | Buy |
125,640
+70,284
| +127% | +$496K | ﹤0.01% | 1024 |
|
|
2021
Q3 | $386K | Buy |
+55,356
| New | +$386K | ﹤0.01% | 1061 |
|
|
2020
Q3 | – | Sell |
-234,000
| Closed | -$725K | – | 1178 |
|
|
2020
Q2 | $725K | Buy |
+234,000
| New | +$725K | ﹤0.01% | 889 |
|
|
2019
Q4 | – | Sell |
-440,346
| Closed | -$1.35M | – | 792 |
|
|
2019
Q3 | $1.35M | Buy |
440,346
+427,379
| +3,296% | +$1.31M | 0.01% | 456 |
|
|
2019
Q2 | $26K | Sell |
12,967
-69,784
| -84% | -$140K | ﹤0.01% | 942 |
|
|
2019
Q1 | $357K | Buy |
+82,751
| New | +$357K | ﹤0.01% | 808 |
|